Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03977155 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
A Phase 2 study, sponsored by Boston Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT03977155 is a Phase 2 study that has completed, run by Boston Pharmaceuticals. The registered enrollment target is 133 participants.
The verdict
NCT03977155, a Phase 2 study, has completed, sponsored by Boston Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and tolerability of BOS-589 in the treatment of IBS-D during 4 weeks of treatment, relative to placebo (PBO).
Interventions
- DRUG Placebo
- DRUG BOS-589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2019-06-04 |
| Est. Completion | 2020-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03977155
The ClinicalTrials.gov registry entry for NCT03977155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03977155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03977155 about?
NCT03977155 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)". This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and tolerability of BOS-589 in the treatment of IBS-D during 4 weeks of treatment,...
What is the current status of trial NCT03977155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2019-06-04. Estimated completion is 2020-05-06.
What interventions are being tested in trial NCT03977155?
The interventions under investigation include: Placebo (DRUG), BOS-589 (DRUG).
Who is sponsoring clinical trial NCT03977155?
This trial is sponsored by Boston Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.